Aprocitentan is under clinical development by Idorsia Pharmaceutical and currently in Phase III for Resistant Hypertension. According to GlobalData, Phase III drugs for Resistant Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Aprocitentan LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aprocitentan overview

Aprocitentan (Tryvio) acts as an antihypertensive agent. It is formulated as film-coated tablets for oral route of administration. It is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.

Aprocitentan (ACT-132577) is under development for the treatment of resistant hypertension. It is administered by oral route in the form of tablet. The drug candidate is an active metabolite of macitentan. It is a dual ETA-ETB antagonist. It was also under development for the treatment of mild to moderate essential hypertension. It is a new molecular entity (NME).

Idorsia Pharmaceutical overview

Idorsia Pharmaceutical (Idorsia) is a biopharmaceutical company that discovers, develops, and commercializes small molecules to treat the central nervous system and cardiovascular and immunological disorders. It is investigating daridorexant against insomnia; aprocitentan for the treatment of resistant hypertension; clazosentan to treat cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage; and L-lucerastat compound targeting fabry disease. The company is also evaluating drugs against suspected acute myocardial infarction, systemic lupus erythematosus, Binge eating disorder and rare lysosomal storage disorders. It works in collaboration with Janssen Biotech to develop and commercialize aprocitentan drug candidates. Idorsia is headquartered in Allschwil, Switzerland.

For a complete picture of Aprocitentan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.